No Improvement With Temozolomide Dose Intensification or Treatment Prolongation
No Survival Benefit of Adding Bevacizumab to Standard of Care, Despite Improved PFS
Promise of Personalized Treatment Strategies Has Not Yet Delivered for Glioblastoma and Other Gliomas
Trials of EGFR Inhibition in Recurrent Glioblastoma Invariably Failed
Why Did We Fail, Despite the Prominent Role of EGFR Signalling in Glioblastoma?
Current Approaches to Targeted Therapies: Ligand‑Compound Constructs
Depatux-M: Toxicity Profile: Response and Duration of Study in Phase 1 Expansion Cohorts on EGFR-Amplified Recurrent GBM
Depatux-M: Clinical Development Program:INTELLANCE1 and INTELLANCE2 Pivotal Studies